Home / Health / MA Weight-Loss Drug Coverage Plummets 52% in 2026
MA Weight-Loss Drug Coverage Plummets 52% in 2026
17 Sep
Summary
- Massachusetts sees 52% drop in GLP-1 weight loss drug coverage by 2026.
- Spending on these drugs doubled annually between 2019 and 2025.
- Insurers anticipate a price crash, potentially restoring coverage.
In Massachusetts, a significant shift in insurance coverage for GLP-1 drugs, widely used for weight loss, is taking effect. By 2026, approximately 112,000 fewer insured individuals will have their GLP-1 prescriptions for weight loss covered, marking a 52% decrease from 2025. This reduction follows years of escalating costs, with spending on these drugs nearly doubling annually between 2019 and 2025.
The surge in GLP-1 drug expenses placed a substantial burden on employers and residents, with private insurance spending nearing $1 billion in 2025. As coverage ends for weight-loss indications, spending is projected to decrease to $662 million in 2026. Insurers continue to cover GLP-1s for diabetes treatment.
Despite current cutbacks, there is optimism for future access. Health officials anticipate a "major price crash" for GLP-1s as new drugs enter the market, potentially enabling insurance coverage to resume within a few years. The Health Policy Commission will continue to monitor the evolving market and its impact on healthcare access.
